According to the Zhongtong Finance APP, Sihuan Pharm (00460) rose nearly 4%. As of press time, it rose 3.85% to HKD 0.54, with a turnover of HKD 1.9742 million.

On the news front, Sihuan Pharma announced that its subsidiary Xuanzhu Biopharmaceutical and Livzon Pharma have reached an exclusive licensing agreement for XZP-5849, a PDE5 inhibitor independently developed by Xuanzhu Biopharmaceutical. Under the agreement, Livzon Pharma will obtain exclusive development, production and commercialization rights to XZP-5849 in the non-standard market areas of Greater China, while Xuanzhu Biopharmaceutical will retain the development, production and commercialization rights to XZP-5849 in Europe, the United States, Japan, South Korea, Australia and Brazil. Xuanzhu Biopharmaceutical will receive a prepayment and is entitled to milestone payments and a graded share of sales after the product is launched.